BUSINESS/FINANCIAL/HEALTH EDITORS TVT-Dox binding specificity to tumor vasculature receptor CD13 is confirmed. Procyon Biopharma Inc. (TSX:PBP), a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced today that preclinical results with its novel tumor vasculature targeting drug, TVT-Dox (Tumor Vasculature Targeting liposomal doxorubicin), were presented at the 2006 Miami Nature Biotechnology Winter Symposium Angiogenesis in Cancer and Vascular Disease being held in Miami Beach, February 4-7, 2006.
